ATP6V0A4
V-type proton ATPase 116 kDa subunit a 4
Also known as: a4, ATP6N1B, ATP6N2, RDRTA2, RTA1C, RTADR, Stv1, Vph1, VPP2, VPP4_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9HBG4
- Gene
- ATP6V0A4
- Ensembl
- ENSG00000105929
- Chromosome
- 7
- Canonical length
- 840 aa
- Protein class
- Disease related genes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters
- Subcellular location
- Cytosol
OverviewNCBI Gene
This gene encodes a component of vacuolar ATPase (V-ATPase), a multisubunit enzyme that mediates acidification of intracellular compartments of eukaryotic cells. V-ATPase dependent acidification is necessary for such intracellular processes as protein sorting, zymogen activation, receptor-mediated endocytosis, and synaptic vesicle proton gradient generation. V-ATPase is composed of a cytosolic V1 domain and a transmembrane V0 domain. The V1 domain consists of three A and three B subunits, two G subunits plus the C, D, E, F, and H subunits. The V1 domain contains the ATP catalytic site. The V0 domain consists of five different subunits: a, c, c', c'', and d. This gene is one of four genes in man and mouse that encode different isoforms of the a subunit. Alternatively spliced transcript variants encoding the same protein have been described. Mutations in this gene are associated with renal tubular acidosis associated with preserved hearing. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
840 residues, UniProt reviewed canonical sequence.
>Q9HBG4|ATP6V0A4
1 MVSVFRSEEM CLSQLFLQVE AAYCCVAELG ELGLVQFKDL NMNVNSFQRK FVNEVRRCES
61 LERILRFLED EMQNEIVVQL LEKSPLTPLP REMITLETVL EKLEGELQEA NQNQQALKQS
121 FLELTELKYL LKKTQDFFET ETNLADDFFT EDTSGLLELK AVPAYMTGKL GFIAGVINRE
181 RMASFERLLW RICRGNVYLK FSEMDAPLED PVTKEEIQKN IFIIFYQGEQ LRQKIKKICD
241 GFRATVYPCP EPAVERREML ESVNVRLEDL ITVITQTESH RQRLLQEAAA NWHSWLIKVQ
301 KMKAVYHILN MCNIDVTQQC VIAEIWFPVA DATRIKRALE QGMELSGSSM APIMTTVQSK
361 TAPPTFNRTN KFTAGFQNIV DAYGVGSYRE INPAPYTIIT FPFLFAVMFG DCGHGTVMLL
421 AALWMILNER RLLSQKTDNE IWNTFFHGRY LILLMGIFSI YTGLIYNDCF SKSLNIFGSS
481 WSVQPMFRNG TWNTHVMEES LYLQLDPAIP GVYFGNPYPF GIDPIWNLAS NKLTFLNSYK
541 MKMSVILGIV QMVFGVILSL FNHIYFRRTL NIILQFIPEM IFILCLFGYL VFMIIFKWCC
601 FDVHVSQHAP SILIHFINMF LFNYSDSSNA PLYKHQQEVQ SFFVVMALIS VPWMLLIKPF
661 ILRASHRKSQ LQASRIQEDA TENIEGDSSS PSSRSGQRTS ADTHGALDDH GEEFNFGDVF
721 VHQAIHTIEY CLGCISNTAS YLRLWALSLA HAQLSEVLWT MVMNSGLQTR GWGGIVGVFI
781 IFAVFAVLTV AILLIMEGLS AFLHALRLHW VEFQNKFYVG DGYKFSPFSF KHILDGTAEELocalizationUniProt · AlphaFold · HPA
Whether an antibody against ATP6V0A4 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 8
- Mean surface accessibility (rSASA)
- 0.32
- Highest tissue expression
- 74 nTPM
Expression across tissuesHPA
Tissue
- salivary gland: 74 nTPM
- kidney: 59 nTPM
- skin: 9.9 nTPM
- choroid plexus: 5 nTPM
- esophagus: 4.6 nTPM
- breast: 4.4 nTPM
Single-cell type
- renal collecting duct intercalated cells: 1,092 nCPM
- distal convoluted tubule cells: 561 nCPM
- renal connecting tubule cells: 362 nCPM
- salivary duct cells: 309 nCPM
- epididymal clear cells: 278 nCPM
- salivary ionocytes: 224 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- choroid plexus: 7 nTPM
- hippocampal formation: 1.4 nTPM
- cerebral cortex: 1.2 nTPM
- amygdala: 0.8 nTPM
- basal ganglia: 0.8 nTPM
- medulla oblongata: 0.7 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about ATP6V0A4.
Disease | AllUniProt
Conditions ATP6V0A4 is implicated in, by any mechanism.
- Renal tubular acidosis, distal, 3, with or without sensorineural hearing loss (DRTA3) MIM:602722
Disease | GeneticClinVar
87 pathogenic / likely-pathogenic of 646 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Renal tubular acidosis, distal, 3, with or without sensorineural hearing loss
- Autosomal recessive distal renal tubular acidosis
- ATP6V0A4-related disorder
- Distal renal tubular acidosis
- Renal tubulopathies
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.85
- DepMap mean gene effect
- -0.04
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- intracellular pH reduction
- ossification
- proton transmembrane transport
- regulation of pH
- renal tubular secretion
- sensory perception of sound
- synaptic vesicle lumen acidification
- vacuolar acidification
Molecular functions
Cellular components
- apical part of cell
- apical plasma membrane
- basolateral plasma membrane
- brush border membrane
- endosome
- endosome membrane
- extracellular exosome
- lysosomal membrane
- phagocytic vesicle membrane
- plasma membrane
- proton-transporting V-type ATPase complex
- synaptic vesicle membrane
- vacuolar proton-transporting V-type ATPase complex
- vacuolar proton-transporting V-type ATPase, V0 domain
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ATP6V0A4 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ATP6V0A4 as an antibody target. Whether an autoantibody or antibody against ATP6V0A4 could matter depends on whether native ATP6V0A4 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ATP6V0A4 is annotated at the cell surface, where native ATP6V0A4 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label ATP6V0A4 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...